Les négociations relatives à la dérogation à l’Accord ADPIC demeurent incertaines en amont de la CM12

Report an error

Summary

AI-generated

This summary is written by a language model reading the source document. It is not the publisher's words and is not a substitute for the original.

Learn more about AI enrichment

The briefing examines the tension between intellectual property rights and public health during the COVID-19 pandemic, specifically focusing on the proposed TRIPS waiver. It details the shift from a broad proposal by India and South Africa to a more limited 'quadrilateral' compromise involving the US and EU, while noting the role of the WHO's C-TAP initiative.

Key insights

AI-generated

These insights are written by a language model reading the source document. They are not the publisher's words and are not a substitute for the original.

Learn more about AI enrichment
  • In October 2020, India and South Africa proposed a waiver of the TRIPS Agreement covering sections 1, 4, 5, and 7 of Part II, which relate to copyrights, industrial designs, patents, and undisclosed information, to facilitate the prevention and treatment of COVID-19.
  • The European Union opposed the initial waiver proposal, arguing that intellectual property rights were not a primary barrier to accessing COVID-19 technologies, and instead proposed a counter-plan focused on trade facilitation, production expansion, and the use of compulsory licenses.
  • A 'quadrilateral' group consisting of the US, EU, India, and South Africa developed a compromise text that significantly narrowed the scope of the original proposal; while the original sought waivers for 40 articles, the compromise focused on a single paragraph regarding exports under non-voluntary authorization.
  • The US administration insisted that the waiver be limited strictly to vaccines and explicitly exclude China, asserting that China does not require the waiver because it possesses both COVID-19 vaccines and mRNA technology.
  • The World Health Organization established the COVID-19 Technology Access Pool (C-TAP) in May 2020 following a request from Costa Rica to pool intellectual property, clinical data, and know-how for pandemic response.
  • In May 2022, US President Joe Biden announced a licensing agreement involving the US National Institutes of Health, C-TAP, and the Medicines Patent Pool, covering 11 technologies including the stabilized spike protein used in vaccines.

Cite the original document

APA
Balasubramaniam, T. (n.d.). Les négociations relatives à la dérogation à l’Accord ADPIC demeurent incertaines en amont de la CM12. International Institute for Sustainable Development. https://www.iisd.org/fr/node/16626
Chicago
Balasubramaniam, Thiru. Les négociations relatives à la dérogation à l’Accord ADPIC demeurent incertaines en amont de la CM12. International Institute for Sustainable Development, n.d. https://www.iisd.org/fr/node/16626.
Wikipedia
{{cite report |last1=Balasubramaniam |first1=Thiru |title=Les négociations relatives à la dérogation à l’Accord ADPIC demeurent incertaines en amont de la CM12 |publisher=International Institute for Sustainable Development |url=https://www.iisd.org/fr/node/16626 |access-date=23 October 2026 |via=Climate Insights Directory}}
BibTeX
@techreport{balasubramaniamndles, author = {Balasubramaniam, Thiru}, title = {{Les négociations relatives à la dérogation à l’Accord ADPIC demeurent incertaines en amont de la CM12}}, institution = {International Institute for Sustainable Development}, url = {https://www.iisd.org/fr/node/16626}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }

Full text

Collected · Record updated